Combined anticancer activity of osthole and cisplatin in NCI-H460 lung cancer cells in vitro

14Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

Abstract

Drug combination therapies are common practice in the treatment of cancer. Cisplatin is the most active chemotherapeutic agent for lung cancer treatment. Osthole is a natural compound extracted from a number of medicinal plants. To determine whether osthole enhances the anticancer effect of cisplatin in human lung cancer, we treated NCI-H460 cells with osthole alone or in combination with cisplatin and evaluated cell growth and apoptosis using 3-(4,5-dimethyl thiazol-2yl)-2,5-diphenyltetrazolium bromide (MTT) assay, flow cytometry and fluorescence microscopy. The results showed that, in comparison with single agent treatment, the combination of osthole and cisplatin resulted in greater efficacy in growth inhibition and apoptosis induction. Western blot analysis revealed that the combination effect of osthole and cisplatin was due to regulation of the Bcl-2 family proteins. Findings of this investigation suggested that osthole combined with cisplatin is a potential clinical chemotherapeutic approach in human lung cancer.

Cite

CITATION STYLE

APA

Xu, X. M., Zhang, Y., Qu, D., Liu, H. B., Gu, X., Jiao, G. Y., & Zhao, L. (2013). Combined anticancer activity of osthole and cisplatin in NCI-H460 lung cancer cells in vitro. Experimental and Therapeutic Medicine, 5(3), 707–710. https://doi.org/10.3892/etm.2013.889

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free